Hillhurst Biopharmaceuticals
San Diego
About Hillhurst Biopharmaceuticals
Hillhurst has created technology that allows low-dose carbon monoxide to be used therapeutically (CO). Their medicines that arise target a protective cellular metabolic system of heme oxygenase, that is hypothesized to reduce inflammatory processes, prevent cell death, and stop hemoglobin polymerization in sickle cell disease. Despite overwhelming evidence of CO's potential efficacy as a therapy, it has not been commercially feasible to dose carbon monoxide. The methods of administration that have been tried, such as breathing CO and CO bound to a carrier like co releasing molecules/CORMS and CO prodrugs, have significant drawbacks. These hurdles for inhaled co include caregiver inhalation exposure due to the need for pressurized co gas cylinders and imprecise dosing.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $11.3M
- Funding stage: Seed
- Last round: Grant (May 2025)
- Website: hillhurstbio.com
- Phone: +1 818 445 5890
Industries & Categories
Advanced Materials, Alternative Medicine, Biotechnology, Life Science, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/hillhurst-biopharmaceuticals-71109 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.